Home > Newsletters > FDAnews Drug Daily Bulletin > Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
FDAnews Drug Daily Bulletin
Oct. 10, 2012 | Vol. 9 No. 199
Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors. The trial compared vatreptacog alfa with Novo’s FDA-approved NovoSeven [coagulation factor VIIa (recombinant)] to treat 567 bleeding episodes in 72 hemophiliacs.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.